Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Isatuximab nel trattamento di pazienti con mieloma plasmacellulare ad alto rischio

5 ottobre 2026 aggiornato da: M.D. Anderson Cancer Center

Sperimentazione di fase II a braccio singolo di Isatuximab (SAR650984) in pazienti con mieloma multiplo smoldering ad alto rischio

This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.

Panoramica dello studio

Stato

Attivo, non reclutante

Descrizione dettagliata

PRIMARY OBJECTIVE:

- To determine the rate of response according to the International Myeloma Working Group Criteria.

SECONDARY OBJECTIVES:

  • To determine progression free survival (PFS) at 2 years.
  • To determine overall survival (OS).
  • To determine duration of response (DOR).
  • To determine the clinical benefit rate (CBR).
  • To evaluate safety of single agent treatment in this population
  • To evaluate safety of single agent treatment in this population.
  • To evaluate the immunogenicity of isatuximab.

OUTLINE:

Patients on single agent cohort receive isatuximab intravenously (IV) over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles.

Patients on Combination Cohort with Lenalidomide receive isatuximab as in single agent cohort plus Lenalidomide po 21/28 days during cycles 1-6 only. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.

Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6-12 months.

Tipo di studio

Interventistico

Iscrizione (Stimato)

61

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New York
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Stati Uniti, 10029
        • Mount Sinai Hospital
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • M D Anderson Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

-Risk factors for progression to multiple myeloma in patients with smoldering multiple myeloma (SMM) have been identified and include: percentage of bone marrow involvement by plasma cells, monoclonal spike in blood, serum free light chains in blood, presence or absence of immunoparesis in blood, percentage of normal versus abnormal plasma cells in the bone marrow compartment by using standard flow cytometry techniques and gene expression profiling of plasma cells obtained from a bone marrow aspirate.

Patients must have histologically confirmed SMM based on the following criteria. Both criteria must be met:

  1. Serum monoclonal protein (IgG or IgA) ≥ 3 g/dL or urinary monoclonal protein ≥ 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60%
  2. Absence of myeloma defining events or amyloidosis

Additionally, patients must meet criteria for high risk of progression to multiple myeloma by PETHEMA criteria (patients must have at least 2 risk factors present) (11):

  • ≥95% abnormal plasma cells/total plasma cells in bone marrow compartment. (This is measured as a percentage of the total abnormal versus normal plasma cells in the bone marrow compartment using standard flow cytometry of the bone marrow aspirate. Having ≥95% abnormal plasma cells/total plasma cells constitutes a risk factor for progression to multiple myeloma by PETHEMA criteria)

  • Immunoparesis (This term refers to the patient having low uninvolved immunoglobulins in peripheral blood, for example if a patient has IgA smoldering multiple myeloma, then either having a low IgM and/or low IgG will qualify as a risk factor for progression to multiple myeloma)

    *2 of 2 risk factors: high risk for progression at a rate of 72% at 5 years

  • Creatinine clearance (CrCl) ≥ 40 ml/min. CrCl will be calculated using the Modification of Diet in Renal Disease (MDRD) equation.

  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of isatuximab in patients <18 years of age, children are excluded from this study.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Absolute neutrophil count (ANC) ≥ 1.0 x 109 /L, hemoglobin more or equal than 2 grams below the institutional level of normal and platelet count ≥ 90 x 109/L. Platelet and blood transfusions are allowed on protocol. Growth factors, including granulocyte colony stimulating factors and erythropoietin are allowed.

  • Adequate hepatic function, with bilirubin < 1.5 x the ULN, and AST and ALT < 3.0 x ULN.

  • Females of childbearing potential and male subjects with female partners of childbearing potential must agree to avoid pregnancy by using an adequate method of contraception (2 barrier method or 1 barrier method with a spermicide or intrauterine device for 10-14 days prior to screening, during and 5 months after the last dose of isatuximab. Adequate methods of contraception are provided as examples. Other acceptable and effective methods of birth control are also permitted (eg, abstinence).

  • Men must agree to not donate sperm while on the study and for at least 5 months after the last dose of isatuximab. Women of child bearing potential must have a negative serum/urine pregnancy test result within 10-14 days prior to the first administration of isatuximab and at the end of treatment visit. A negative urine pregnancy test is required prior to each subsequent isatuximab dose administration.

  • Subjects must be able to give informed consent.

Exclusion Criteria:

  • Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following(14)

    1. Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL)
    2. Renal Insufficiency: creatinine clearance < 50 ml/min or serum creatinine > 2 mg/dL
    3. Anemia: hemoglobin value <10 g/dL or 2 g/dL < normal reference
    4. Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT).
    5. Clonal bone marrow plasma cell percentage ≥ 60%
    6. Involved: uninvolved serum free light chain ratio ≥100 measured by Freelite assay (The Binding Site Group, Birmingham, UK)
    7. >1 focal lesions on MRI studies (each focal lesion must be 5 mm or more in size)
  • Bisphosphonates are permitted, including pamidronate, zoledronic acid, alendronate, ibandronate, risedronate.

  • Treatment with corticosteroids is not permitted, unless the patient is on a stable chronic dose of inhaled steroids to treat respiratory diseases or on stable chronic steroid replacement therapy for endocrinology disorders.

  • Radiotherapy is not permitted.

  • Prior or concurrent treatment for smoldering multiple myeloma with chemotherapy agents approved for the treatment of smoldering multiple myeloma or CD38 drugs is not permitted.

  • Plasma cell leukemia

  • Pregnant or lactating females. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with isatuximab, breastfeeding should be discontinued if the mother is treated with isatuximab. These potential risks may also apply to other agents used in this study.

  • Active hepatitis B or C infection

  • Known HIV infection

  • Intolerance to infused protein products, sucrose, histidine or polysorbate 80

  • Concurrent treatment with other anti-cancer therapy is not permitted

  • Patients must not have uncontrolled intercurrent illness including hypertension, symptomatic congestive heart failure, unstable angina, uncontrolled cardiac arrhythmia. Patients should not have New York Heart Association classification III or IV heart failure at baseline.

  • Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements

  • Contraindication to any concomitant medication, including pre-medications or hydration given prior to therapy

  • Major surgery within 1 month prior to enrollment

  • Patients with pre-existing pulmonary uncontrolled disease will be excluded. Uncontrolled refers to patients having had at least one hospitalization due to pulmonary disease (for example, asthma, chronic obstructive pulmonary disease) within the 6 months prior to enrollment in the study. Patients with previous history of pneumonitis will be excluded.

  • Recruitment Strategies

  • Patients that are seen in clinic at MD Anderson, Memorial Sloan Kettering Cancer Center and Mount Sinai meeting eligibility criteria will be screened for the protocol

  • Other participant sources will be from outside physician referrals.

  • Our outside physician referral network has a high representation of minorities.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (isatuximab)

Patients receive isatuximab IV over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.

Correlative studies

Given IV

Altri nomi:
  • Hu38SB19
  • RAS 650984
  • SAR650984
  • Sarclissa
  • Isatuximab-irfc

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response (>= partial response)
Lasso di tempo: 6 months

The trial will be conducted by the Simon's optimal two-stage design and the response rate will be estimated accordingly. Summary statistics will be provided for continuous variables. Frequency tables will be used to summarize categorical variables. Logistic regression will be utilized to assess the effect of patient prognostic factors on the response rate and the adverse event rate.

6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression free survival
Lasso di tempo: 2 years

Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test.

2 years
Overall survival
Lasso di tempo: Up to 5 years

Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test.

Up to 5 years
Incidence of adverse events
Lasso di tempo: Up to 5 years

Adverse events will be summarized by frequency tables for all patients. For the safety endpoint, per-treated analysis will be performed to include any patient who received the treatment regardless of the eligibility nor the duration or dose of the treatment received.

Up to 5 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of minimal residual disease (MRD) negativity at complete remission assessed by flow cytometry and next generation sequencing
Lasso di tempo: Up to 2 years

MRD assessed will be based on bone marrow aspirates. Will use 8-color flow cytometry as well as next generation sequencing of the variable (V) diversity (D) joining (J) segment.

Up to 2 years
Molecular profiling
Lasso di tempo: Baseline up to progression of disease, assessed up to 5 years

Will include whole exome sequencing and gene expression profiling and cellular (including flow cytometry) profiling using bone marrow aspirate samples.

Baseline up to progression of disease, assessed up to 5 years
Immune characterization
Lasso di tempo: Baseline up to 2 years

Cell surface and functional studies of dendritic, T-, B-, natural killer (NK)- and NKT-cells using bone marrow aspirate samples and peripheral blood samples.

Baseline up to 2 years
Mechanisms of resistance to isatuximab
Lasso di tempo: Up to 5 years

Will include generation of isatuximab resistant myeloma cells, gene expression profiling in drug-naive and resistant myeloma cells, identification of molecular pathways involved in the generation of the resistant phenotype and mechanisms of dual resistance to isatuximab and other myeloma drugs.

Up to 5 years
Genetic polymorphisms
Lasso di tempo: Baseline

Will include FcGR genetic variations assessed using peripheral blood samples.

Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Sheeba Thomas, MD, M.D. Anderson Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 febbraio 2017

Completamento primario (Stimato)

30 aprile 2027

Completamento dello studio (Stimato)

30 aprile 2030

Date di iscrizione allo studio

Primo inviato

8 novembre 2016

Primo inviato che soddisfa i criteri di controllo qualità

8 novembre 2016

Primo Inserito (Stimato)

9 novembre 2016

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2015-0148
  • 2015-0148 (Altro identificatore: M D Anderson Cancer Center)
  • NCI-2016-01922 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi